BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 14654558)

  • 1. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.
    Pryer NK; Lee LB; Zadovaskaya R; Yu X; Sukbuntherng J; Cherrington JM; London CA
    Clin Cancer Res; 2003 Nov; 9(15):5729-34. PubMed ID: 14654558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
    London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
    Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
    London CA; Hannah AL; Zadovoskaya R; Chien MB; Kollias-Baker C; Rosenberg M; Downing S; Post G; Boucher J; Shenoy N; Mendel DB; McMahon G; Cherrington JM
    Clin Cancer Res; 2003 Jul; 9(7):2755-68. PubMed ID: 12855656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular proliferation in canine cutaneous mast cell tumors: associations with c-KIT and its role in prognostication.
    Webster JD; Yuzbasiyan-Gurkan V; Miller RA; Kaneene JB; Kiupel M
    Vet Pathol; 2007 May; 44(3):298-308. PubMed ID: 17491070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines.
    Takeuchi Y; Fujino Y; Watanabe M; Nakagawa T; Ohno K; Sasaki N; Sugano S; Tsujimoto H
    Vet Immunol Immunopathol; 2010 Oct; 137(3-4):208-16. PubMed ID: 20591500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells.
    Gleixner KV; Rebuzzi L; Mayerhofer M; Gruze A; Hadzijusufovic E; Sonneck K; Vales A; Kneidinger M; Samorapoompichit P; Thaiwong T; Pickl WF; Yuzbasiyan-Gurkan V; Sillaber C; Willmann M; Valent P
    Exp Hematol; 2007 Oct; 35(10):1510-21. PubMed ID: 17681669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.
    Shivakrupa R; Bernstein A; Watring N; Linnekin D
    Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The tyrosine kinase inhibitor imatinib [STI571] induces regression of xenografted canine mast cell tumors in SCID mice.
    Kobie K; Kawabata M; Hioki K; Tanaka A; Matsuda H; Mori T; Maruo K
    Res Vet Sci; 2007 Apr; 82(2):239-41. PubMed ID: 16919303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors.
    Webster JD; Kiupel M; Yuzbasiyan-Gurkan V
    BMC Cancer; 2006 Apr; 6():85. PubMed ID: 16579858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
    Yancey MF; Merritt DA; Lesman SP; Boucher JF; Michels GM
    J Vet Pharmacol Ther; 2010 Apr; 33(2):162-71. PubMed ID: 20444041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catching cancer by the tail: new perspectives on the use of kinase inhibitors.
    Khanna C; Gordon I
    Clin Cancer Res; 2009 Jun; 15(11):3645-7. PubMed ID: 19470723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A>T mutation via suppression of constitutive KIT activation.
    Yamada O; Kobayashi M; Sugisaki O; Ishii N; Ito K; Kuroki S; Sasaki Y; Isotani M; Ono K; Washizu T; Bonkobara M
    Vet Immunol Immunopathol; 2011 Jul; 142(1-2):101-6. PubMed ID: 21561667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of dysregulation of the receptor tyrosine kinases Kit, Flt3, and Met in histiocytic sarcomas of dogs.
    Zavodovskaya R; Liao AT; Jones CL; Yip B; Chien MB; Moore PF; London CA
    Am J Vet Res; 2006 Apr; 67(4):633-41. PubMed ID: 16579756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of c-kit mutations-independent neoplastic cell proliferation of canine mast cells.
    Ohmori K; Kawarai S; Yasuda N; Tanaka A; Matsuda H; Nishimura R; Sasaki N; Tsujimoto H; Masuda K
    Vet Immunol Immunopathol; 2008 Nov; 126(1-2):43-53. PubMed ID: 18687474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of proto-oncogene C-kit and correlation with morphological evaluations in canine cutaneous mast cell tumors.
    Passantino L; Passantino G; Cianciotta A; Ribaud MR; Lo Presti G; Ranieri G; Perillo A
    Immunopharmacol Immunotoxicol; 2008; 30(3):609-21. PubMed ID: 18608529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Canine subcutaneous mast cell tumors: cellular proliferation and KIT expression as prognostic indices.
    Thompson JJ; Yager JA; Best SJ; Pearl DL; Coomber BL; Torres RN; Kiupel M; Foster RA
    Vet Pathol; 2011 Jan; 48(1):169-81. PubMed ID: 21160022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors.
    Kiupel M; Webster JD; Kaneene JB; Miller R; Yuzbasiyan-Gurkan V
    Vet Pathol; 2004 Jul; 41(4):371-7. PubMed ID: 15232137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.
    Liao AT; Chien MB; Shenoy N; Mendel DB; McMahon G; Cherrington JM; London CA
    Blood; 2002 Jul; 100(2):585-93. PubMed ID: 12091352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphorylated KIT as a predictor of outcome in canine mast cell tumours treated with toceranib phosphate or vinblastine.
    Thamm DH; Weishaar KM; Charles JB; Ehrhart EJ
    Vet Comp Oncol; 2020 Jun; 18(2):169-175. PubMed ID: 31365175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fyn kinase acts upstream of Shp2 and p38 mitogen-activated protein kinase to promote chemotaxis of mast cells towards stem cell factor.
    Samayawardhena LA; Hu J; Stein PL; Craig AW
    Cell Signal; 2006 Sep; 18(9):1447-54. PubMed ID: 16442778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.